生命科学资讯

MoonLake's phase 2 arthritis win kicks off pivotal year for IL-17 nanobody

Gilead to acquire cell therapy partner Arcellx for $7.8B

Microfluidics Research Report 2026-2035: A $20.73 Billion - GlobeNewswire

Microfluidics Research Report 2026-2035: A $20.73 Billion Market by 2030 with Thermo Fisher Scientific, PerkinElmer, Dolomite, Agilent Technologies, Bio-Rad Laboratories, and Fluidigm Leading - Yahoo Finance

Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial

Operating a new standard for life-saving pharmaceutical logistics

All about cell therapy process characterization

Assessing Myelin Formation and Therapeutic Response Using 3D Organoids

iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson’s and First Enrollment in China’s Randomized MSA Trial for NouvNeu004

High-throughput neutralization measurements correlate strongly with evolutionary success of human influenza strains

Scaling up efforts to target evolving viruses

MoonLake has 'confidence' ahead of FDA submission, discloses mid-stage arthritis win

Illumina Beat Q4 Earnings and Closed a $350M Acquisition. Here’s What Investors Need to Know - TIKR.com

Tredje AP fonden Sells 32,000 Shares of Thermo Fisher Scientific Inc. $TMO - MarketBeat

Thermo Fisher Scientific Inc. $TMO Stock Holdings Raised by Raiffeisen Bank International AG - MarketBeat

Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and more

Vanda gets FDA approval for ‘franchise-extending’ antipsychotic

Grail's cancer test faces new uncertainty after UK study

Supreme Court steps in: Trump's emergency tariffs struck down

Ionis scraps early candidate for Alzheimer’s in people with Down syndrome